Novartis AG Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Novartis AG (NVS) reported Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $234.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2026-02-04
| Period end | Expense From Cashsettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2025-12-31 | $234.00M 20-F · filed 2026-02-04 |
| 2024-12-31 | $263.00M 20-F · filed 2026-02-04 |
| 2023-12-31 | $277.00M 20-F · filed 2026-02-04 |